Mutations in the human SAMHD1 gene are known to correlate with the development of the Aicardi-Goutières syndrome (AGS), which is an inflammatory encephalopathy that exhibits neurological dysfunction characterized by increased production of type I interferon (IFN); this evidence has led to the concept that the SAMHD1 protein negatively regulates the type I IFN response. Additionally, the SAMHD1 protein has been shown to prevent efficient HIV-1 infection of macrophages, dendritic cells, and resting CD4+ T cells. To gain insights on the SAMHD1 molecular determinants that are responsible for the deregulated production of type I IFN, we explored the biochemical, cellular, and antiviral properties of human SAMHD1 mutants known to correlate with the development of AGS. Most of the studied SAMHD1 AGS mutants exhibit defects in the ability to oligomerize, decrease the levels of cellular deoxynucleotide triphosphates in human cells, localize exclusively to the nucleus, and restrict HIV-1 infection. At least half of the tested variants preserved the ability to be degraded by the lentiviral protein Vpx, and all of them interacted with RNA. Our investigations revealed that the SAMHD1 AGS variant p.G209S preserve all tested biochemical, cellular, and antiviral properties, suggesting that this residue is a determinant for the ability of SAMHD1 to negatively regulate the type I IFN response in human patients with AGS. Overall, our work genetically separated the ability of SAMHD1 to negatively regulate the type I IFN response from its ability to restrict HIV-1.
INTRODUCTION
Mutations in the human SAMHD1 gene (MIM# 606754) have been linked to the development of Aicardi-Goutières syndrome (AGS), a genetic disease characterized by increased expression of interferon alpha (IFN-), which closely mimics congenital viral infection (Dale et al., 2010; du Moulin, Nurnberg, Crow, & Rutsch, 2011; LeshinskySilver et al., 2011; Ramantani et al., 2011; Rice et al., 2009; Thiele et al., 2010) . AGS is considered an interferonopathie in which upregulation of type I IFN activity directly correlates with disease progression (Crow & Manel, 2015) . AGS has also been shown to be caused by mutations in the 3 ′ -5 ′ exonuclease TREX1 (Crow et al., 2006) , the components of the RNASEH2 endonuclease complex: RNASEH2A, RNASEH2B, and RNASEH2C (Rice et al., 2009) , the cytosolic doublestranded RNA (dsRNA) sensor MDA5 (Miner & Diamond, 2014) , and the dsRNA editing enzyme ADAR1 (Pestal et al., 2015; Rice et al., 2012) . Since all known AGS mutations have been linked to proteins involved in nucleic acid metabolism, it has been hypothesized that AGS is caused by an increase in cellular nucleic acid debris that activates the cellular innate IFN--mediated immune response by mimicking viral infection (Crow et al., 2006) . The type I IFN response is tightly regulated and requires the cellular recognition of pathogen-associated molecular patterns via pattern recognition receptors (PRR's). PRR's include Toll-like receptors that sense nucleic acids, RIG-I-like receptors that sense RNA, and cyclic GMP-AMP synthase (cGAS), which senses DNA and activates the ER-associated stimulator of IFN genes protein (STING) pathway (Habjan & Pichlmair, 2015; Wu & Chen, 2014) . Mutations in TREX1 linked to AGS have been shown to cause increased cellular nucleic acid levels and activate the innate immune response (Crow et al., 2006; Fye, Orebaugh, Coffin, Hollis, & Perrino, 2011 Stetson et al., 2008) . The TREX1-deficient mice display chronic IFN production, as seen in AGS (Gray et al., 2015) . In addition, the TREX1-deficient mice exhibit a reduced survival and develop inflammatory myocarditis (Morita et al., 2004) . When the TREX1-deficient mice is crossed with IFN-receptor 1-deficient mice, progeny display no phenotypic differences compared to wild-type mice demonstrating the need for IFN-signaling in the development of the phenotype (Stetson et al., 2008) . In agreement with the hypothesis that SAMHD1 modulates the type I IFN response (Rice et al., 2009) , the SAMHD1-deficient mice also exhibit higher basal levels of type I IFN (Behrendt et al., 2013; Rehwinkel et al., 2013) .
Recent work identified SAMHD1 as the protein that blocks infection of SIV∆Vpx, HIV-2∆Vpx, and HIV-1 before reverse transcription in macrophages, dendritic cells, and resting CD4+ T cells (Baldauf et al., 2012; Berger et al., 2011; Descours et al., 2012; Hrecka et al., 2011; Laguette et al., 2011) . The SAMHD1 protein comprises the sterile alpha motif and histidine-aspartic (HD) domains. The HD domain of SAMHD1 is a dGTP-regulated deoxynucleotide triphosphohydrolase that decreases the cellular levels of deoxynucleotide triphosphates (dNTPs) (Goldstone et al., 2011; Kim, Nguyen, Daddacha, & Hollenbaugh, 2012; Lahouassa et al., 2012; Powell, Holland, Hollis, & Perrino, 2011) . The sole HD domain is sufficient to potently restrict infection by different viruses (White et al., 2013a) . The HD domain is also necessary for the ability of SAMHD1 to oligomerize and to bind RNA (White et al., 2013a) . The antiviral activity of SAMHD1 is regulated by phosphorylation (Cribier, Descours, Valadao, Laguette, & Benkirane, 2013; Welbourn, Dutta, Semmes, & Strebel, 2013; White et al., 2013b) . Interestingly, an antivirally active SAMHD1 is unphosphorylated on T592. By contrast, SAMHD1 phosphorylated on T592 is antivirally inactive. These findings showed that contrary to what happens in cycling cells, SAMHD1 is unphosphorylated in noncycling cells. These results proposed an explanation for the reason that SAMHD1 is expressed in cycling and noncycling cells, but it only exhibits antiviral activity in noncycling cells.
The human population contains a large number of SAMHD1 variants that are associated with the development of AGS. We and others have previously defined the biochemical, cellular, and antiviral properties of SAMHD1 by developing a series of robust assays (BrandarizNunez et al., 2012b; Cribier et al., 2013; Kim et al., 2012; Lahouassa et al., 2012; White et al., 2013a; White et al., 2013b) . To gain insights on the molecular determinants of SAMHD1 that are involved in the development of AGS, we have characterized a large panel of SAMHD1 AGS mutants that are known to correlate with increased levels of type I IFN in human patients (Rice et al., 2013) . For this purpose, we tested the different human SAMHD1 AGS variants that increase levels of type I IFN in human patients for antiviral activity, oligomerization, RNA binding, subcellular localization, Vpx-mediated degradation, and their ability to decrease the cellular levels of dNTPs in human cells.
MATERIALS AND METHODS

Cell lines and plasmids
Human U937 (ATCC# CRL-1593.2) cells were grown in RPMI supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin. Human HeLa (ATCC# CCL-2) cells were grown on DMEM supplemented with 10% (v/v) fetal bovine serum and 1% (v/v) penicillin/streptomycin. LPCX-SAMHD1-HA and LPCX-SAMHD1-FLAG plasmids expressing the codon optimized SAMHD1 (MIM# 606754, RefSeq NM_015474.3) fused to either HA or FLAG epitope were previously described (Brandariz-Nunez et al., 2012b) .
The plasmids-expressing SAMHD1 mutants were created using pLPCX-SAMHD1-FLAG as template and specific primers. PCR products were digested and cloned into the EcoRI and ClaI sites of pLPCX.
Orientation of the inserts was confirmed by sequencing and restriction analysis.
Generation of U937 cells stably expressing SAMHD1 variants
Retroviral vectors encoding wild-type or mutant SAMHD1 proteins fused to FLAG were created using the LPCX vector (Clontech). Recombinant viruses were produced in 293FT cells by cotransfecting the LPCX plasmids with the pVPack-GP and pVPack-VSV-G packaging plasmids (Stratagene). The pVPack-VSV-G plasmid encodes the vesicular stomatitis virus G envelope glycoprotein, which allows efficient entry into a wide range of vertebrate cells (Yee, Friedmann, & Burns, 1994) . Transduced human monocytic U937 cells were selected in 0.4 g/ml puromycin (Sigma).
Protein analysis
Cellular proteins were extracted with radioimmunoprecipitation assay as previously described (Lienlaf et al., 2011) . Detection of proteins by Western blotting was performed using anti-FLAG (Sigma; Cat # F7425), anti-GAPDH (Ambion; Cat # 4300), or anti-HA (Sigma; Cat # 3663). Secondary antibodies against rabbit and mouse conjugated to Alexa Fluor 680 were obtained from Li-Cor. Bands were detected by scanning blots using the Li-Cor Odyssey Imaging System in the 700-nm channel.
Infection with retroviruses expressing the green fluorescent protein
Recombinant retroviruses expressing green fluorescent protein (GFP), pseudotyped with the VSV-G glycoprotein, were prepared as described (Diaz-Griffero et al., 2008) . For infections, 6 × 10 4 cells seeded in 24-well plates and were either treated with either concentration 10 ng/ml phorbol-12-myristate-3-acetate (PMA) or DMSO for 16 hr. PMA stock solution was prepared in DMSO at 250 g/ml. Cat# 11836170001]). Lysates were incubated at 4°C with gentle rocking for 45 min and centrifuged at 14,000 rpm for 1 hr at 4°C. Post-spin lysates were then precleared using protein A-agarose (bioWORLD; Cat# 20181028-1) for 1 hr at 4°C with gentle rocking; a small aliquot of each of these lysates was stored as input. Precleared lysates containing the tagged proteins were incubated with anti-FLAG-agarose beads (Sigma; Cat# A2220) for 2 hr at 4°C with gentle rocking. Anti-FLAGagarose beads were washed three times in WCE buffer changing the tube between the second and third washes, and immune complexes were eluted using 100 l of 200 g/ml FLAG tripeptide (Sigma; Cat# F4799) in WCE buffer for 1 hr upright with gentle rocking at 4°C. The eluted samples were separated by SDS-PAGE and analyzed by Western blotting using either anti-HA or anti-FLAG antibodies.
SAMHD1 oligomerization assay
Nucleic acid binding assay
Nucleic acid binding assay was performed as previously described (Goncalves et al., 2012) . In brief, the synthetic DNA phosphorothioatecontaining interferon-stimulatory DNA (ISD-PS), which is an RNA analog, was synthesized with a 5 ′ -biotin tag using the following primers:
ISD sense 5 ′ -tacagatctactagtgatctatgactgatctgtacatgatctaca-3 ′ , ISD antisense 5 ′ -tgtagatcatgtacagatcagtcatagatcactagtagatctgta-3 ′ Sense and antisense primers were incubated at 65°C for 20 min, and primers were allowed to anneal by cooling down to room temperature.
Annealed primers were immobilized on a Ultralink Immobilized Streptavidin Plus Gel (Pierce). Cells were lysed using TAP lysis buffer (50 mM Tris pH 7.5, 100 mM NaCl, 5% glycerol, 0.2% NP-40, 1.5 mM MgCl 2 , 25 mM NaF, 1 mM Na 3 VO 4 , protease inhibitors), and lysates were cleared by centrifugation. Cleared lysates (input) were incubated with immobilized nucleic acids at 4°C on a rotary wheel for 2 hr in the presence of 10 g/ml of Calf-thymus DNA (Sigma) as a competitor. Unbound proteins were removed by three consecutive washes in TAP lysis buffer.
Bound proteins to nucleic acids (immunoprecipitation) were eluted by boiling samples in SDS sample buffer (63 mM Tris-HCl, 10% glycerol 2% SDS, 0.0025% bromophenol blue) and analyzed by Western blotting using anti-FLAG antibodies (Sigma).
Transfections and immunofluorescence microscopy
Transfections of cell monolayers were performed using Lipofectamine Plus reagent (Invitrogen), according to the manufacturer's instructions. Transfections were incubated at 37°C for 24 hr. Indirect immunofluorescence microscopy was performed as previously described (Diaz-Griffero, 2002) . Transfected monolayers grown on coverslips were washed twice with PBS and fixed for 15 min in 3.9% paraformaldehyde in PBS. Fixed cells were washed twice in PBS, permeabilized for 4 min in permeabilizing buffer (0.5% Triton X-100 in PBS), and then blocked in PBS containing 2% bovine serum albumin(blocking buffer) for 1 hr at room temperature. Cells were then incubated for 1 hr at room temperature with primary antibodies diluted in blocking buffer. After three washes with PBS, cells were incubated for 30 min in secondary antibodies and 1 g of DAPI (49, 69-diamidino-2-phenylindole)/ml. Samples were mounted for fluorescence microscopy by using the ProLong Antifade Kit (Molecular Probes, Eugene, OR). Images were obtained with a Zeiss Observer.Z1 microscope using a 63X objective, and deconvolution was performed using the software AxioVision V4.8.1.0 (Carl Zeiss Imaging Solutions).
RESULTS
The ability of SAMHD1 AGS variants to restrict HIV-1
Although it is established that SAMHD1-deficient CD14 + cells derived from an AGS patient containing the SAMHD1 mutation p.R164X are susceptible to HIV-1 infection (Berger et al., 2011) , the ability of most SAMHD1 AGS mutants to restrict HIV-1 has not been studied. To this end, we generated a series of SAMHD1 AGS mutant constructs. For these studies, we selected a comprehensive list of human SAMHD1 mutants expressed in patients that exhibit increased levels of type I IFN ( Fig. 1A ; Table 1 ) (Rice et al., 2009; Rice et al., 2013) . The indicated SAMHD1 variants were stably expressed in the human monocytic cell line U937 by using the LPCX vector system (Fig. 1A and B), as previously described (Brandariz-Nunez et al., 2012b) . As shown in Figure 1B , the different SAMHD1 variants are well expressed in the human U937 cell line. U937 cells stably expressing SAMHD1 variants were induced to differentiate by PMA treatment to a noncycling state (Fig. 1C) (Schwende, Fitzke, Ambs, & Dieter, 1996) . Differentiated U937 cells were challenged with increasing amounts of HIV-1 viruses containing the GFP as a reporter (HIV-1-GFP) ( Fig. 1C ; Table 1 ). As a control, we performed similar infections in PMA-treated U937 cells containing the empty vector LPCX. As expected, wild-type SAMHD1 blocked HIV-1 infection; however, all variants tested except for p.G209S lost the ability to restrict HIV-1 infection. p.G209S is among the first mutations found to correlate with the development of AGS (Rice et al., 2009 (Arnold et al., 2015; Ryoo et al., 2014) . The HIV-1 restriction by the SAMHD1 AGS variants p.H123P, p.R143C, p.R143H, p.R145Q, and p.R290H was not determined due to lack of expression. F I G U R E 1 Characterization of the ability of the different SAMHD1 AGS variants to restrict HIV-1 infection. A: Human SAMHD1 protein is depicted showing the numbers of the amino acids residues at the boundaries of each domain along with the position and number of each AGS mutant studied here. AGS mutants studies in this work as indicates. The nuclear localization signal, the phosphorylation site on T592, and the Vpx interaction motif are depicted. B: Human monocytic U937 cells stably expressing the indicated mutant and wild-type SAMHD1 proteins were challenged with increasing amounts of HIV-1-GFP. C: Forty hours post infection, the percentage of GFP-positive cells was determined by flow cytometry. As control, U937 cells stably transduced with the empty vector LPCX were challenged with HIV-1-GFP. All SAMHD1 AGS mutant infection experiments were repeated at least three times and a representative figure is shown (Fig. 2) , as we have previously described (White et al., 2013a 
Oligomerization of SAMHD1 AGS variants
C, Cyt; N, nuclear; ND, not determined; WT, wild type. Notes: a Restriction was measured by infecting PMA-treated U937 cells stably expressing the indicated SAMHD1 (NM_015474.3) variants with HIV-1-GFP. After 48 hr, the percentage of GFP-positive cells (infected cells) was determined by flow cytometry. b SAMHD1-FLAG variants were assayed for their ability to oligomerize, as described in Materials and Methods. "+++" indicates 100% oligomerization, which correspond to the amount of SAMHD1-HA that oligomerizes with wild-type SAMHD1-FLAG; "++" indicates ∼60% of binding; "+" indicates ∼30% oligomerization; "-" indicates that oligomerization was not detected. c SAMHD1-FLAG variants were assayed for their ability to interact with RNA as described in Materials and Methods. "+" is the binding achieved by wild-type SAMHD1. d Vpx-dependent degradation of each human SAMHD1 polymorphism was determined as described in Materials and Methods. "+" indicates similar Vpxmediated SAMHD1 degradation to the one observed for wild-type SAMHD1; "-" indicates that degradation was not detected. e The cellular dNTP levels of U937 cells stably expressing the different SAMHD1 variants were determined as described in Materials and Methods. "High" indicates that SAMHD1 is unable to decrease the levels of dNTPs. "Low" indicates similar dNTP levels to the ones observed for U937 cells stably expressing wild-type SAMHD1. f Subcellular localization of SAMHD1 variants was determined as described in Materials and Methods and quantified (Supp. Table S1 ). "N" indicates nuclear localization; "C" indicates cytoplasmic localization; "N+C" indicates localization throughout the cell.
F I G U R E 2
Oligomerization of mutant and wild-type SAMHD1 proteins. Human 293T cells were cotransfected with a plasmid expressing wildtype SAMHD1-HA and a plasmid either expressing wild-type or mutant SAMHD1-FLAG proteins. Cells were lysed 24 hr after transfection and analyzed by Western blotting using anti-HA and anti-FLAG antibodies (input). Subsequently, lysates were immunoprecipitated by using anti-FLAG agarose beads, as described in Materials and Methods. Anti-FLAG agarose beads were eluted using FLAG peptide, and elutions were analyzed by Western blotting using anti-HA and anti-FLAG antibodies (immunoprecipitation). Similar results were obtained in three independent experiments and representative data is shown. WB, Western blot; IP, immunoprecipitation; WT, wild type F I G U R E 3 SAMHD1 AGS mutants binding to nucleic acids. Human 293T cells were transfected with plasmid expressing the indicated wild-type and mutant SAMHD1 protein. Cells were lysed 24 hr after transfection (input), and were incubated with ISD-PS immobilized in StrepTactin Superflow affinity resin. Similarly, eluted proteins from the resin were visualized by Western blotting using anti-FLAG antibodies (bound). Similar results were obtained in three independent experiments and a representative experiment is shown. ISD-PS, interferon-stimulatory DNA sequence containing a phosphorothioate backbone; WB, Western blot; WT, wild type we have previously reported (Brandariz-Nunez et al., 2013 
SAMHD1 AGS variants binding to nucleic acids
Previous experiments demonstrated the ability of SAMHD1 to interact with nucleic acids (Goncalves et al., 2012; Seamon, Sun, Shlyakhtenko, Lyubchenko, & Stivers, 2015; Tungler et al., 2013; White et al., 2013a; White et al., 2013b) . Previous work has demonstrated that SAMHD1 preferentially binds RNA by testing the ability of SAMHD1 from total mammalian or bacterial extracts to bind the IFN-stimulatory DNA sequence containing a phosphorothioate backbone (ISD-PS), which is an RNA analog (Goncalves et al., 2012; White et al., 2013a; White et al., 2013b) . These experiments raised the possibility that SAMHD1 is directly interacting with RNA. Here, we wanted to know whether the SAMHD1 variants described in this work bind RNA. To assay the ability of SAMHD1 variants to bind RNA, we tested the ability of SAMHD1 variants produced in human 293T cells to bind ISD-PS ( Fig. 3; Table 1 ).
Analysis of binding to RNA revealed that every SAMHD1 AGS variant tested binds RNA ( Fig. 3; Table 1 ). In agreement with a previous report, we found that all SAMHD1 AGS variants containing an intact Nterminal region of the HD domain till residue R442 interact with RNA (Goncalves et al., 2012) (Fig. 3; Table 1 ).
Subcellular localization of SAMHD1 AGS variants
Previous work has demonstrated that SAMHD1 is a nuclearly localized protein (Brandariz-Nunez et al., 2012b; Hofmann et al., 2012; F I G U R E 4 Intracellular distribution of SAMHD1 AGS variant proteins in HeLa cells. HeLa cells expressing the indicated SAMHD1-FLAG variants were fixed and immunostained using antibodies against FLAG (red). Cellular nuclei were stained by using DAPI (blue). Nuclear and cytosolic distribution was quantified (Supp . Table S1 ) F I G U R E 5 Vpx-dependent degradation of SAMHD1 variants. HeLa cells were cotransfected with plasmids expressing the indicated SAMHD1 variants and HA-tagged Vpx from HIV-2 ROD (Vpx ROD ) or SIV RCM (Vpx rcm ). Thirty-six hours after transfection, cells were harvested, and the expression levels of SAMHD1 and Vpx were analyzed by Western blotting using anti-FLAG and anti-HA antibodies. As a loading control, cell extracts were Western blotted using antibodies against GAPDH. Similar results were obtained in three independent experiments and a representative experiment is shown Rice et al., 2009; Schaller, Pollpeter, Apolonia, Goujon, & Malim, 2014) .
Next, we investigated the subcellular localization of the SAMHD1 variants studied on this work in the human HeLa cells (Fig. 4 ; Supp. (Fig. 4 ; Supp. Fig. S1 ; Supp. Table   S1 ). The nuclear and cytoplasmic localization for some of the SAMHD1 AGS variants is in agreement with a previous report (Goncalves et al., 2012) . Interestingly, p.G209S and p.D311A showed nuclear localization similar to wild-type SAMHD1.
Ability of Vpx to degrade human SAMHD1 polymorphisms
Because the viral protein Vpx from different viruses induces the degradation of SAMHD1 (Hrecka et al., 2011; Laguette et al., 2012; Laguette et al., 2011) , we tested the ability of Vpx from HIV-2 ROD (Vpx ROD ) to degrade the different SAMHD1 variants, as previously described (White et al., 2013a) . For this purpose, we cotransfected the different human SAMHD1 polymorphisms together with Vpx ROD and measured the expression level of SAMHD1 (Fig. 5) . As a control, we cotransfected the different human SAMHD1 variants with Vpx SIV rcm (Vpx rcm ), which is unable to induce the degradation of human SAMHD1 (Brandariz-Nunez et al., 2012a; White et al., 2013a) . As shown in Figure 5 , we observed that the SAMHD1 variants p.R145Q, p. H167Y, p.I201N, p.G209S, p.F217C, p.R226G, p.R290H , p.D311A, p.L369S, and p.Q548A were degraded by Vpx ROD (Table 1) . By contrast, SAMHD1 variants p.H123P, p.R143C, p.R143H, p.M254V, p.M385V, and p.I448T were not degraded by Vpx ROD . Also, in agreement with previous reports, SAMHD1 p.R442X and p.Q548X were not degraded by Vpx ROD (Ahn et al., 2012; Laguette et al., 2012; Lim et al., 2012; Zhang et al., 2012) .
Level of cellular dNTPs in U937 cells stably expressing the different SAMHD1 AGS mutants
Previous observations have suggested that SAMHD1 decreases the intracellular pool of dNTPs (Goldstone et al., 2011; Kim et al., 2012; Lahouassa et al., 2012; Powell et al., 2011; White et al., 2013a) . To test whether different human SAMHD1 proteins are affected in their ability to decrease the cellular levels of dNTPs, we measured the levels of dATP, dTTP, and dGTP in U937 cells stably expressing the different SAMHD1 AGS variants. As shown in Figure 6 , of all the tested SAMHD1 AGS polymorphisms, only p.G209S and p.Q548A were able to decrease the cellular levels of dNTPs. These findings are in agreement with a recent report showing that SAMHD1 p.Q548A retains the ability to decrease the cellular levels of dNTPs (Ryoo et al., 2014) .
The ability of the SAMHD1 AGS variants p.H123P, p.R143C, p.R143H, p.R145Q, and p.R290H to decrease cellular dNTP levels was not determined due to lack of expression.
DISCUSSION
This work explores the different properties of human SAMHD1 mutations associated with an increased production of type I IFN and the F I G U R E 6 Cellular dATP, dTTP, and dGTP levels in U937 cells stably expressing the different SAMHD1 variants. Quantification of dATP, dTTP, and dGTP levels on PMA-treated U937 cells expressing the indicated SAMHD1 variants was performed by a primer extension assay as previously described. Similar results were obtained in three independent experiments and standard deviation is shown. "*" Indicates statistical significance compared to U937 cells expressing WT SAMHD1 as determined by an unpaired Student's t-test with P > 0.05. WT, wild type development of AGS in humans. We initially tested for the ability of these mutants to block HIV-1 infection. Of the tested SAMHD1 AGS mutants, only p.G209S retained the ability to block HIV-1 infection.
Although most of the tested human SAMHD1 AGS mutations lose their ability to block HIV-1 infection, the discovery of an AGS mutant that retains the ability to restrict HIV-1 infection but loses the ability to protect individuals from AGS suggests that these two phenotypes are the result of distinguishable functions.
The SAMHD1 p.G209S variant along with a subset of the SAMHD1 AGS mutants characterized here have been shown to lose the ability to inhibit LINE-1 retrotransposition (Zhao et al., 2013) . Because human and mouse cells that are knockout for the expression of SAMHD1 exhibit elevated production of type I IFNs (Behrendt et al., 2013; Kretschmer et al., 2015; Rehwinkel et al., 2013; Roesch & Schwartz, 2013; Zhang et al., 2015) , one hypothesis is that the inability of SAMHD1 p.G209S to interfere with LINE-1 replication allows innate immune sensors to recognize LINE-1, consequentially triggering an IFN response. This hypothesis is in agreement with recent findings suggesting that the spontaneous IFN response in SAMHD1-deficient mice requires the cGAS/STING cytosolic DNA-sensing pathway (Maelfait et al., 2016) . Altogether, these experiments suggest that expression of the SAMHD1 p.G209S mutant or the absence of SAMHD1 expression in patients leads to the sensing of DNA, RNA, or DNA/RNA species, by sensors such as cGAS/STING(DNA and DNA/RNA hybrids), RIG-I(RNA), or MDA5(RNA), which triggers a type I IFN response (Mankan et al., 2014; Wu & Chen, 2014) . This suggests that SAMHD1 might be preventing the production or the sensing of nucleic acids. Inhibition of LINE-1 retrotransposition is an example of preventing the formation of these nucleic acid species, and it is possible that SAMHD1 is preventing the formation of other yet unknown nucleic acid species that trigger inflammatory signals. In agreement with the observation that SAMHD1 interacts with nucleic acids (Goncalves et al., 2012; Seamon et al., 2015; White et al., 2013a) , it is also conceivable that SAMHD1 binds to nucleic acids, sterically obstructing the detection of these nucleic acids by the sensors cGAS/STING, RIG-I, or MDA5, preventing the induction of type I IFN. Future investigations will distinguish the mechanism that is used by SAMHD1 to negatively modulate the type I IFN response.
Previous reports have established the oligomerization nature of SAMHD1 (Brandariz-Nunez et al., 2013; Ji et al., 2014; White et al., 2013a; Yan et al., 2013) . Next, we thoroughly characterize the oligomerization properties of the different SAMHD1 mutants using our established assay to detect oligomerization of SAMHD1 proteins in mammalian cells (Brandariz-Nunez et al., 2013; White et al., 2013a; White et al., 2013b) . Our results indicated that most of the SAMHD1 AGS variants tested lost their oligomerization properties, at least to some extent, with the exception of p.G209S, p.M254V, p.D311A, and p.Q548A, which were found to oligomerize similar to wild-type SAMHD1.
Because SAMHD1 has the ability to bind RNA in vitro (Goncalves et al., 2012; Seamon et al., 2015; White et al., 2013a) , we tested the ability of SAMHD1 variants to bind RNA. All tested human SAMHD1 polymorphisms retained the ability to bind the RNA analogue ISD-PS in vitro. Overall, these results suggest that the affinity of SAMHD1 for RNA is difficult to abolish.
Because Vpx triggers the degradation of SAMHD1 (Hrecka et al., 2011; Laguette et al., 2011) , we tested the ability of Vpx to induce the degradation of the different human SAMHD1 proteins. Consistent with the degradation requirement for Vpx ROD to bind to the C-terminus of SAMHD1 (Laguette et al., 2012; Yan et al., 2013) , we found that the truncation mutants p.R442X and p.Q548X were not degraded by Vpx ROD . In addition, the full-length SAMHD1 variants p.H123P, p.R143C, p.R143H, p.M254V, p.M385V, and p.I448T were resistant to Vpx ROD -induced degradation when compared with wildtype SAMHD1, which is in agreement with the notion that other regions of SAMHD1, besides the C-terminus, are required for Vpxinduced degradation (Lim et al., 2012) . In a separate report, investigators have proposed a model in which Vpx interacts with the oligomeric interface of SAMHD1, suggesting that oligomeric SAMHD1 is required for its interaction with Vpx (Fregoso et al., 2013 We also tested the nuclear localization of the different human SAMHD1 variants. In agreement with previous work, none of the studied human SAMHD1 variants are N-terminal truncations or contain mutations in the nuclear localization signal and therefore none of the variants studied here lost the ability to localize to the nucleus. We did take note, however, that all SAMHD1 variants tested except for p.G209S and p.D311A localized to the cytosol. In contrast to a previous report, we found that the p.G209S mutant localizes mostly to the nucleus (Goncalves et al., 2012) . These differences might be due to that we are using HeLa cells from different origin.
Next, we tested the ability of the different SAMHD1 variants to decrease the cellular levels of dNTPs. All of the SAMHD1 variants tested here lost their ability to decrease cellular levels of dNTPs, except for p.G209S and p.Q548A. Interestingly, the SAMHD1 variant, p.Q548A, decreases the levels of dNTPs in human cells, but do not restrict HIV-1, suggesting that the ability of SAMHD1 to decrease the cellular levels of dNTPs is necessary but not sufficient to restrict HIV-1 infection (Cribier et al., 2013; Welbourn & Strebel, 2016; Welbourn et al., 2013; White et al., 2013b) . SAMHD1 has the ability to decrease the cellular levels of dNTPs in human cells (Goldstone et al., 2011; Kim et al., 2012; Lahouassa et al., 2012; Powell et al., 2011; White et al., 2013a) , which was initially correlated to the ability of SAMHD1 to block HIV-1 infection. This notion has been challenged by SAMHD1 mutations on T592 that decrease the cellular levels of dNTPs but no longer restrict HIV-1 infection (Cribier et al., 2013; Welbourn et al., 2013; White et al., 2013b) .
Combined with previous observations, this suggests the existence of at least three SAMHD1 variants that decrease the cellular levels of dNTPs and do not restrict HIV-1: p.T592D, p.T592E, and p.Q548A. In agreement, the oligomerization defective mutant Y146S/Y154S displays a severe dNTPase defect in vitro, but is indistinguishable from wild type SAMHD1 in its ability to deplete cellular dNTP pools and to restrict HIV replication (Bhattacharya et al., 2016; Brandariz-Nunez et al., 2013) , suggesting that the dNTPase activity of SAMHD1 might be necessary but is not sufficient for restriction.
Phosphorylation of SAMHD1 does not seem to regulate the enzymatic activity (dNTPase) of the protein in vitro. Several publications have demonstrated that recombinant SAMHD1-T592D/E or immunoprecipitated from human cells showed no effect on its enzymatic activity (dNTPase) when compared to the wild type protein (Arnold et al., 2015; Bhattacharya et al., 2016; Welbourn et al., 2013; Welbourn & Strebel, 2016; White et al., 2013b) . Only one publication showed that purified SAMHD1-T592E exhibit a decreased dNTPase activity (Tang, Ji, Wu, & Xiong, 2015) . Collectively, this evidence suggested that phosphorylation of T592 does not affect the dNTPase activity of the protein in vitro. Interestingly, in the case of human U937 cells, expression of phosphomimetic mutants pT592D or p.T592E in PMA-treated U937 cells deplete cellular dNTPs but do not restrict HIV-1, suggesting that depletion of dNTPs in cells is required but not sufficient for HIV-1 restriction (Bhattacharya et al., 2016; White et al., 2013b) . Similarly, the oligomerization-defective mutant p.[(Y146S;
Y154S)] decreases the cellular levels of dNTPs and no longer block HIV-1 infection (Bhattacharya et al., 2016; Brandariz-Nunez et al., 2013) . The work presented here adds to the growing number of SAMHD1 variants (p.Q548A) that decrease the levels of dNTPs and no longer block HIV-1 infection.
Finally, the SAMHD1 variant, p.G209S, blocks HIV-1 infection, but is unable to negatively regulate the type I IFN response in humans affected with AGS, suggesting that p.G209S genetically separates the ability of SAMHD1 to restrict HIV-1 from the ability of SAMHD1 to negatively regulate the type I IFN response in humans. We believe that this mutant represents an instrumental genetic tool to understand the molecular role of SAMHD1 in the type I IFN response and in the development of AGS.
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